nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—CHEK2—peripheral nervous system neoplasm	0.293	0.497	CbGaD
Bosutinib—ALK—peripheral nervous system neoplasm	0.262	0.443	CbGaD
Bosutinib—ABCB1—peripheral nervous system neoplasm	0.0357	0.0604	CbGaD
Bosutinib—Gefitinib—CHEK2—peripheral nervous system neoplasm	0.00272	0.892	CrCbGaD
Bosutinib—TLK1—ganglion—peripheral nervous system neoplasm	0.00185	0.0232	CbGeAlD
Bosutinib—RPS6KB1—forelimb—peripheral nervous system neoplasm	0.00157	0.0197	CbGeAlD
Bosutinib—WEE1—ganglion—peripheral nervous system neoplasm	0.00148	0.0185	CbGeAlD
Bosutinib—STK25—ganglion—peripheral nervous system neoplasm	0.00141	0.0177	CbGeAlD
Bosutinib—EPHB3—nerve—peripheral nervous system neoplasm	0.00111	0.014	CbGeAlD
Bosutinib—BMPR2—ganglion—peripheral nervous system neoplasm	0.00111	0.0139	CbGeAlD
Bosutinib—MERTK—ganglion—peripheral nervous system neoplasm	0.00109	0.0136	CbGeAlD
Bosutinib—CLK1—ganglion—peripheral nervous system neoplasm	0.00101	0.0127	CbGeAlD
Bosutinib—CAMK2G—nerve—peripheral nervous system neoplasm	0.001	0.0126	CbGeAlD
Bosutinib—LRRK2—nerve—peripheral nervous system neoplasm	0.000996	0.0125	CbGeAlD
Bosutinib—CAMK2G—ganglion—peripheral nervous system neoplasm	0.000992	0.0125	CbGeAlD
Bosutinib—LRRK2—ganglion—peripheral nervous system neoplasm	0.000983	0.0123	CbGeAlD
Bosutinib—EPHA4—nerve—peripheral nervous system neoplasm	0.00093	0.0117	CbGeAlD
Bosutinib—EPHA4—ganglion—peripheral nervous system neoplasm	0.000919	0.0115	CbGeAlD
Bosutinib—EPHA4—tongue—peripheral nervous system neoplasm	0.000909	0.0114	CbGeAlD
Bosutinib—ULK3—ganglion—peripheral nervous system neoplasm	0.000908	0.0114	CbGeAlD
Bosutinib—ULK3—tongue—peripheral nervous system neoplasm	0.000898	0.0113	CbGeAlD
Bosutinib—EIF2AK1—trigeminal ganglion—peripheral nervous system neoplasm	0.000811	0.0102	CbGeAlD
Bosutinib—PRKCQ—brainstem—peripheral nervous system neoplasm	0.000791	0.00992	CbGeAlD
Bosutinib—VRK2—trigeminal ganglion—peripheral nervous system neoplasm	0.000786	0.00986	CbGeAlD
Bosutinib—SYK—trigeminal ganglion—peripheral nervous system neoplasm	0.000771	0.00967	CbGeAlD
Bosutinib—CDK2—trigeminal ganglion—peripheral nervous system neoplasm	0.000763	0.00958	CbGeAlD
Bosutinib—ROCK1—Irinotecan—Topotecan—peripheral nervous system neoplasm	0.000763	0.162	CbGdCrCtD
Bosutinib—FES—parotid gland—peripheral nervous system neoplasm	0.000741	0.0093	CbGeAlD
Bosutinib—VRK2—parotid gland—peripheral nervous system neoplasm	0.000741	0.0093	CbGeAlD
Bosutinib—EPHB2—brainstem—peripheral nervous system neoplasm	0.000725	0.0091	CbGeAlD
Bosutinib—WEE1—trigeminal ganglion—peripheral nervous system neoplasm	0.000725	0.00909	CbGeAlD
Bosutinib—DMPK—trigeminal ganglion—peripheral nervous system neoplasm	0.000725	0.00909	CbGeAlD
Bosutinib—STK25—trigeminal ganglion—peripheral nervous system neoplasm	0.000692	0.00868	CbGeAlD
Bosutinib—MAP4K4—Irinotecan—Topotecan—peripheral nervous system neoplasm	0.00068	0.145	CbGdCrCtD
Bosutinib—PLK2—trigeminal ganglion—peripheral nervous system neoplasm	0.000673	0.00844	CbGeAlD
Bosutinib—STK25—parotid gland—peripheral nervous system neoplasm	0.000652	0.00819	CbGeAlD
Bosutinib—CAMK1D—trigeminal ganglion—peripheral nervous system neoplasm	0.000636	0.00798	CbGeAlD
Bosutinib—PLK2—parotid gland—peripheral nervous system neoplasm	0.000634	0.00796	CbGeAlD
Bosutinib—FER—trigeminal ganglion—peripheral nervous system neoplasm	0.000608	0.00763	CbGeAlD
Bosutinib—EPHA5—trigeminal ganglion—peripheral nervous system neoplasm	0.000608	0.00763	CbGeAlD
Bosutinib—IKBKE—cerebellum—peripheral nervous system neoplasm	0.000597	0.00749	CbGeAlD
Bosutinib—BTK—trigeminal ganglion—peripheral nervous system neoplasm	0.000593	0.00744	CbGeAlD
Bosutinib—EPHB2—Irinotecan—Topotecan—peripheral nervous system neoplasm	0.000579	0.123	CbGdCrCtD
Bosutinib—MAP4K2—trigeminal ganglion—peripheral nervous system neoplasm	0.000576	0.00723	CbGeAlD
Bosutinib—EPHB3—trigeminal ganglion—peripheral nervous system neoplasm	0.00054	0.00678	CbGeAlD
Bosutinib—TYRO3—brainstem—peripheral nervous system neoplasm	0.000538	0.00675	CbGeAlD
Bosutinib—MAP4K4—trigeminal ganglion—peripheral nervous system neoplasm	0.000524	0.00658	CbGeAlD
Bosutinib—NUAK2—trigeminal ganglion—peripheral nervous system neoplasm	0.000521	0.00653	CbGeAlD
Bosutinib—BCR—trigeminal ganglion—peripheral nervous system neoplasm	0.000521	0.00653	CbGeAlD
Bosutinib—MAP3K12—trigeminal ganglion—peripheral nervous system neoplasm	0.000517	0.00649	CbGeAlD
Bosutinib—CSK—trigeminal ganglion—peripheral nervous system neoplasm	0.000503	0.00631	CbGeAlD
Bosutinib—ERBB4—brainstem—peripheral nervous system neoplasm	0.000503	0.00631	CbGeAlD
Bosutinib—CSNK1A1—trigeminal ganglion—peripheral nervous system neoplasm	0.0005	0.00627	CbGeAlD
Bosutinib—HCK—trigeminal ganglion—peripheral nervous system neoplasm	0.000497	0.00623	CbGeAlD
Bosutinib—CLK1—trigeminal ganglion—peripheral nervous system neoplasm	0.000497	0.00623	CbGeAlD
Bosutinib—NUAK2—parotid gland—peripheral nervous system neoplasm	0.000491	0.00616	CbGeAlD
Bosutinib—BCR—parotid gland—peripheral nervous system neoplasm	0.000491	0.00616	CbGeAlD
Bosutinib—BMP2K—trigeminal ganglion—peripheral nervous system neoplasm	0.000487	0.00612	CbGeAlD
Bosutinib—LRRK2—trigeminal ganglion—peripheral nervous system neoplasm	0.000483	0.00606	CbGeAlD
Bosutinib—BMPR2—brainstem—peripheral nervous system neoplasm	0.000482	0.00605	CbGeAlD
Bosutinib—EPHB3—brainstem—peripheral nervous system neoplasm	0.000478	0.006	CbGeAlD
Bosutinib—CSK—parotid gland—peripheral nervous system neoplasm	0.000474	0.00595	CbGeAlD
Bosutinib—CSNK1A1—parotid gland—peripheral nervous system neoplasm	0.000471	0.00592	CbGeAlD
Bosutinib—CLK1—parotid gland—peripheral nervous system neoplasm	0.000468	0.00588	CbGeAlD
Bosutinib—CSNK1E—trigeminal ganglion—peripheral nervous system neoplasm	0.000463	0.00581	CbGeAlD
Bosutinib—MAP3K12—brainstem—peripheral nervous system neoplasm	0.000457	0.00574	CbGeAlD
Bosutinib—IRAK4—trigeminal ganglion—peripheral nervous system neoplasm	0.000456	0.00572	CbGeAlD
Bosutinib—SIK1—trigeminal ganglion—peripheral nervous system neoplasm	0.000456	0.00572	CbGeAlD
Bosutinib—STK35—brainstem—peripheral nervous system neoplasm	0.000448	0.00562	CbGeAlD
Bosutinib—MAP2K1—brainstem—peripheral nervous system neoplasm	0.000448	0.00562	CbGeAlD
Bosutinib—MAP2K2—trigeminal ganglion—peripheral nervous system neoplasm	0.000446	0.00559	CbGeAlD
Bosutinib—ULK3—trigeminal ganglion—peripheral nervous system neoplasm	0.000446	0.00559	CbGeAlD
Bosutinib—MAST1—cerebellum—peripheral nervous system neoplasm	0.000444	0.00557	CbGeAlD
Bosutinib—MAP3K7—trigeminal ganglion—peripheral nervous system neoplasm	0.000438	0.0055	CbGeAlD
Bosutinib—CASK—Irinotecan—Topotecan—peripheral nervous system neoplasm	0.000438	0.0932	CbGdCrCtD
Bosutinib—CSNK1E—parotid gland—peripheral nervous system neoplasm	0.000437	0.00548	CbGeAlD
Bosutinib—TBK1—trigeminal ganglion—peripheral nervous system neoplasm	0.000433	0.00544	CbGeAlD
Bosutinib—CAMK2G—brainstem—peripheral nervous system neoplasm	0.000431	0.00541	CbGeAlD
Bosutinib—SIK1—parotid gland—peripheral nervous system neoplasm	0.00043	0.0054	CbGeAlD
Bosutinib—IRAK4—parotid gland—peripheral nervous system neoplasm	0.00043	0.0054	CbGeAlD
Bosutinib—LRRK2—brainstem—peripheral nervous system neoplasm	0.000427	0.00536	CbGeAlD
Bosutinib—ULK3—parotid gland—peripheral nervous system neoplasm	0.00042	0.00528	CbGeAlD
Bosutinib—RPS6KB1—trigeminal ganglion—peripheral nervous system neoplasm	0.000417	0.00523	CbGeAlD
Bosutinib—LCK—trigeminal ganglion—peripheral nervous system neoplasm	0.000414	0.0052	CbGeAlD
Bosutinib—MAP3K7—parotid gland—peripheral nervous system neoplasm	0.000414	0.00519	CbGeAlD
Bosutinib—AXL—trigeminal ganglion—peripheral nervous system neoplasm	0.000413	0.00518	CbGeAlD
Bosutinib—TBK1—parotid gland—peripheral nervous system neoplasm	0.000409	0.00513	CbGeAlD
Bosutinib—EPHA4—brainstem—peripheral nervous system neoplasm	0.000399	0.00501	CbGeAlD
Bosutinib—SLK—trigeminal ganglion—peripheral nervous system neoplasm	0.000397	0.00499	CbGeAlD
Bosutinib—TLK1—cerebellum—peripheral nervous system neoplasm	0.000395	0.00496	CbGeAlD
Bosutinib—EPHB4—trigeminal ganglion—peripheral nervous system neoplasm	0.000394	0.00495	CbGeAlD
Bosutinib—RPS6KB1—parotid gland—peripheral nervous system neoplasm	0.000393	0.00494	CbGeAlD
Bosutinib—PRKCQ—cerebellum—peripheral nervous system neoplasm	0.00039	0.00489	CbGeAlD
Bosutinib—EPHA2—trigeminal ganglion—peripheral nervous system neoplasm	0.000387	0.00486	CbGeAlD
Bosutinib—FYN—trigeminal ganglion—peripheral nervous system neoplasm	0.000386	0.00485	CbGeAlD
Bosutinib—STK33—cerebellum—peripheral nervous system neoplasm	0.000385	0.00483	CbGeAlD
Bosutinib—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.000378	0.167	CbGbCtD
Bosutinib—ABCB1—Topotecan—peripheral nervous system neoplasm	0.000378	0.167	CbGbCtD
Bosutinib—MAP4K5—trigeminal ganglion—peripheral nervous system neoplasm	0.000378	0.00474	CbGeAlD
Bosutinib—MAP3K3—trigeminal ganglion—peripheral nervous system neoplasm	0.000378	0.00474	CbGeAlD
Bosutinib—PKMYT1—cerebellum—peripheral nervous system neoplasm	0.000375	0.0047	CbGeAlD
Bosutinib—SLK—parotid gland—peripheral nervous system neoplasm	0.000375	0.0047	CbGeAlD
Bosutinib—EPHB4—parotid gland—peripheral nervous system neoplasm	0.000372	0.00467	CbGeAlD
Bosutinib—CLK3—cerebellum—peripheral nervous system neoplasm	0.000366	0.00459	CbGeAlD
Bosutinib—DSTYK—cerebellum—peripheral nervous system neoplasm	0.000366	0.00459	CbGeAlD
Bosutinib—EPHA2—parotid gland—peripheral nervous system neoplasm	0.000365	0.00458	CbGeAlD
Bosutinib—PHKG1—cerebellum—peripheral nervous system neoplasm	0.000358	0.00449	CbGeAlD
Bosutinib—CASK—cerebellum—peripheral nervous system neoplasm	0.000358	0.00449	CbGeAlD
Bosutinib—MAP3K3—parotid gland—peripheral nervous system neoplasm	0.000356	0.00447	CbGeAlD
Bosutinib—MAP4K5—parotid gland—peripheral nervous system neoplasm	0.000356	0.00447	CbGeAlD
Bosutinib—EIF2AK1—cerebellum—peripheral nervous system neoplasm	0.000354	0.00444	CbGeAlD
Bosutinib—PTK2—Irinotecan—Topotecan—peripheral nervous system neoplasm	0.000351	0.0745	CbGdCrCtD
Bosutinib—YES1—trigeminal ganglion—peripheral nervous system neoplasm	0.000349	0.00438	CbGeAlD
Bosutinib—STK10—trigeminal ganglion—peripheral nervous system neoplasm	0.000346	0.00434	CbGeAlD
Bosutinib—TAOK3—trigeminal ganglion—peripheral nervous system neoplasm	0.000344	0.00432	CbGeAlD
Bosutinib—EPHA8—cerebellum—peripheral nervous system neoplasm	0.000343	0.0043	CbGeAlD
Bosutinib—FYN—brainstem—peripheral nervous system neoplasm	0.000342	0.00429	CbGeAlD
Bosutinib—TNIK—cerebellum—peripheral nervous system neoplasm	0.000336	0.00422	CbGeAlD
Bosutinib—Gefitinib—ABCB1—peripheral nervous system neoplasm	0.000331	0.108	CrCbGaD
Bosutinib—STK26—cerebellum—peripheral nervous system neoplasm	0.00033	0.00414	CbGeAlD
Bosutinib—YES1—parotid gland—peripheral nervous system neoplasm	0.000329	0.00413	CbGeAlD
Bosutinib—TAOK3—parotid gland—peripheral nervous system neoplasm	0.000325	0.00407	CbGeAlD
Bosutinib—WEE1—cerebellum—peripheral nervous system neoplasm	0.000316	0.00397	CbGeAlD
Bosutinib—DMPK—cerebellum—peripheral nervous system neoplasm	0.000316	0.00397	CbGeAlD
Bosutinib—MAP2K5—trigeminal ganglion—peripheral nervous system neoplasm	0.000309	0.00387	CbGeAlD
Bosutinib—TAOK3—brainstem—peripheral nervous system neoplasm	0.000305	0.00382	CbGeAlD
Bosutinib—STK25—cerebellum—peripheral nervous system neoplasm	0.000302	0.00379	CbGeAlD
Bosutinib—CSF1R—trigeminal ganglion—peripheral nervous system neoplasm	0.000301	0.00378	CbGeAlD
Bosutinib—PLK2—cerebellum—peripheral nervous system neoplasm	0.000293	0.00368	CbGeAlD
Bosutinib—SIK3—cerebellum—peripheral nervous system neoplasm	0.000292	0.00366	CbGeAlD
Bosutinib—MAP2K5—parotid gland—peripheral nervous system neoplasm	0.000291	0.00365	CbGeAlD
Bosutinib—STK4—cerebellum—peripheral nervous system neoplasm	0.000281	0.00352	CbGeAlD
Bosutinib—CAMK1D—cerebellum—peripheral nervous system neoplasm	0.000277	0.00348	CbGeAlD
Bosutinib—STK24—cerebellum—peripheral nervous system neoplasm	0.000274	0.00344	CbGeAlD
Bosutinib—MAP2K5—brainstem—peripheral nervous system neoplasm	0.000273	0.00343	CbGeAlD
Bosutinib—PDGFRB—trigeminal ganglion—peripheral nervous system neoplasm	0.000267	0.00335	CbGeAlD
Bosutinib—FER—cerebellum—peripheral nervous system neoplasm	0.000265	0.00333	CbGeAlD
Bosutinib—EPHA5—cerebellum—peripheral nervous system neoplasm	0.000265	0.00333	CbGeAlD
Bosutinib—TYRO3—cerebellum—peripheral nervous system neoplasm	0.000265	0.00333	CbGeAlD
Bosutinib—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.000262	0.116	CbGbCtD
Bosutinib—TNK2—cerebellum—peripheral nervous system neoplasm	0.000255	0.0032	CbGeAlD
Bosutinib—STK24—Teniposide—Etoposide—peripheral nervous system neoplasm	0.000255	0.0541	CbGdCrCtD
Bosutinib—PDGFRB—parotid gland—peripheral nervous system neoplasm	0.000252	0.00316	CbGeAlD
Bosutinib—MAP4K2—cerebellum—peripheral nervous system neoplasm	0.000251	0.00315	CbGeAlD
Bosutinib—ERBB4—cerebellum—peripheral nervous system neoplasm	0.000248	0.00311	CbGeAlD
Bosutinib—STK3—cerebellum—peripheral nervous system neoplasm	0.000248	0.00311	CbGeAlD
Bosutinib—ABL1—trigeminal ganglion—peripheral nervous system neoplasm	0.000238	0.00299	CbGeAlD
Bosutinib—BMPR2—cerebellum—peripheral nervous system neoplasm	0.000238	0.00298	CbGeAlD
Bosutinib—STK36—cerebellum—peripheral nervous system neoplasm	0.000236	0.00296	CbGeAlD
Bosutinib—EPHB3—cerebellum—peripheral nervous system neoplasm	0.000236	0.00296	CbGeAlD
Bosutinib—MERTK—cerebellum—peripheral nervous system neoplasm	0.000233	0.00292	CbGeAlD
Bosutinib—MAP4K4—cerebellum—peripheral nervous system neoplasm	0.000229	0.00287	CbGeAlD
Bosutinib—NUAK2—cerebellum—peripheral nervous system neoplasm	0.000227	0.00285	CbGeAlD
Bosutinib—BCR—cerebellum—peripheral nervous system neoplasm	0.000227	0.00285	CbGeAlD
Bosutinib—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.000226	0.1	CbGbCtD
Bosutinib—MAP3K12—cerebellum—peripheral nervous system neoplasm	0.000226	0.00283	CbGeAlD
Bosutinib—ABL1—parotid gland—peripheral nervous system neoplasm	0.000225	0.00282	CbGeAlD
Bosutinib—MAP2K1—cerebellum—peripheral nervous system neoplasm	0.000221	0.00277	CbGeAlD
Bosutinib—STK35—cerebellum—peripheral nervous system neoplasm	0.000221	0.00277	CbGeAlD
Bosutinib—CSK—cerebellum—peripheral nervous system neoplasm	0.000219	0.00275	CbGeAlD
Bosutinib—CSNK1A1—cerebellum—peripheral nervous system neoplasm	0.000218	0.00274	CbGeAlD
Bosutinib—CLK1—cerebellum—peripheral nervous system neoplasm	0.000217	0.00272	CbGeAlD
Bosutinib—ABL2—cerebellum—peripheral nervous system neoplasm	0.000215	0.0027	CbGeAlD
Bosutinib—CAMK2G—cerebellum—peripheral nervous system neoplasm	0.000213	0.00267	CbGeAlD
Bosutinib—BMP2K—cerebellum—peripheral nervous system neoplasm	0.000213	0.00267	CbGeAlD
Bosutinib—LRRK2—cerebellum—peripheral nervous system neoplasm	0.000211	0.00264	CbGeAlD
Bosutinib—ABL1—brainstem—peripheral nervous system neoplasm	0.000211	0.00264	CbGeAlD
Bosutinib—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.00021	0.0931	CbGbCtD
Bosutinib—EGFR—cerebellum—peripheral nervous system neoplasm	0.00021	0.00264	CbGeAlD
Bosutinib—PTK2B—cerebellum—peripheral nervous system neoplasm	0.000205	0.00258	CbGeAlD
Bosutinib—CSNK1E—cerebellum—peripheral nervous system neoplasm	0.000202	0.00254	CbGeAlD
Bosutinib—SIK1—cerebellum—peripheral nervous system neoplasm	0.000199	0.0025	CbGeAlD
Bosutinib—IRAK4—cerebellum—peripheral nervous system neoplasm	0.000199	0.0025	CbGeAlD
Bosutinib—EPHA4—cerebellum—peripheral nervous system neoplasm	0.000197	0.00247	CbGeAlD
Bosutinib—ERBB3—cerebellum—peripheral nervous system neoplasm	0.000195	0.00245	CbGeAlD
Bosutinib—MAP2K2—cerebellum—peripheral nervous system neoplasm	0.000195	0.00244	CbGeAlD
Bosutinib—ULK3—cerebellum—peripheral nervous system neoplasm	0.000195	0.00244	CbGeAlD
Bosutinib—MAP3K2—cerebellum—peripheral nervous system neoplasm	0.000193	0.00242	CbGeAlD
Bosutinib—MAP3K7—cerebellum—peripheral nervous system neoplasm	0.000191	0.0024	CbGeAlD
Bosutinib—TBK1—cerebellum—peripheral nervous system neoplasm	0.000189	0.00237	CbGeAlD
Bosutinib—PTK2—cerebellum—peripheral nervous system neoplasm	0.000189	0.00237	CbGeAlD
Bosutinib—IRAK1—cerebellum—peripheral nervous system neoplasm	0.000185	0.00233	CbGeAlD
Bosutinib—RPS6KB1—cerebellum—peripheral nervous system neoplasm	0.000182	0.00228	CbGeAlD
Bosutinib—AXL—cerebellum—peripheral nervous system neoplasm	0.00018	0.00226	CbGeAlD
Bosutinib—SLK—cerebellum—peripheral nervous system neoplasm	0.000173	0.00218	CbGeAlD
Bosutinib—EPHB4—cerebellum—peripheral nervous system neoplasm	0.000172	0.00216	CbGeAlD
Bosutinib—FYN—cerebellum—peripheral nervous system neoplasm	0.000169	0.00212	CbGeAlD
Bosutinib—MAP3K3—cerebellum—peripheral nervous system neoplasm	0.000165	0.00207	CbGeAlD
Bosutinib—MAP4K5—cerebellum—peripheral nervous system neoplasm	0.000165	0.00207	CbGeAlD
Bosutinib—CASK—Teniposide—Etoposide—peripheral nervous system neoplasm	0.000164	0.0349	CbGdCrCtD
Bosutinib—ABCB1—Vincristine—peripheral nervous system neoplasm	0.000161	0.0713	CbGbCtD
Bosutinib—CDK2—Vinblastine—Vincristine—peripheral nervous system neoplasm	0.00016	0.0341	CbGdCrCtD
Bosutinib—YES1—cerebellum—peripheral nervous system neoplasm	0.000152	0.00191	CbGeAlD
Bosutinib—STK10—cerebellum—peripheral nervous system neoplasm	0.000151	0.00189	CbGeAlD
Bosutinib—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.00015	0.0665	CbGbCtD
Bosutinib—TAOK3—cerebellum—peripheral nervous system neoplasm	0.00015	0.00188	CbGeAlD
Bosutinib—WEE1—Daunorubicin—Epirubicin—peripheral nervous system neoplasm	0.000149	0.0317	CbGdCrCtD
Bosutinib—ABCB1—Etoposide—peripheral nervous system neoplasm	0.000148	0.0654	CbGbCtD
Bosutinib—SRC—cerebellum—peripheral nervous system neoplasm	0.000146	0.00184	CbGeAlD
Bosutinib—WEE1—Daunorubicin—Doxorubicin—peripheral nervous system neoplasm	0.000138	0.0293	CbGdCrCtD
Bosutinib—MAP2K5—cerebellum—peripheral nervous system neoplasm	0.000135	0.00169	CbGeAlD
Bosutinib—CSF1R—cerebellum—peripheral nervous system neoplasm	0.000131	0.00165	CbGeAlD
Bosutinib—Dizziness—Topotecan—peripheral nervous system neoplasm	0.000119	0.000835	CcSEcCtD
Bosutinib—Discomfort—Cisplatin—peripheral nervous system neoplasm	0.000119	0.000834	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Vincristine—peripheral nervous system neoplasm	0.000119	0.000833	CcSEcCtD
Bosutinib—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.000118	0.000828	CcSEcCtD
Bosutinib—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.000118	0.000828	CcSEcCtD
Bosutinib—Decreased appetite—Alitretinoin—peripheral nervous system neoplasm	0.000117	0.000825	CcSEcCtD
Bosutinib—Renal impairment—Doxorubicin—peripheral nervous system neoplasm	0.000117	0.000822	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.000117	0.000819	CcSEcCtD
Bosutinib—PDGFRB—cerebellum—peripheral nervous system neoplasm	0.000117	0.00146	CbGeAlD
Bosutinib—Malaise—Etoposide—peripheral nervous system neoplasm	0.000116	0.000819	CcSEcCtD
Bosutinib—Fatigue—Alitretinoin—peripheral nervous system neoplasm	0.000116	0.000818	CcSEcCtD
Bosutinib—Face oedema—Epirubicin—peripheral nervous system neoplasm	0.000116	0.000816	CcSEcCtD
Bosutinib—Leukopenia—Etoposide—peripheral nervous system neoplasm	0.000116	0.000813	CcSEcCtD
Bosutinib—Pain—Alitretinoin—peripheral nervous system neoplasm	0.000115	0.000812	CcSEcCtD
Bosutinib—Body temperature increased—Dactinomycin—peripheral nervous system neoplasm	0.000115	0.000809	CcSEcCtD
Bosutinib—Abdominal pain—Dactinomycin—peripheral nervous system neoplasm	0.000115	0.000809	CcSEcCtD
Bosutinib—Oedema—Cisplatin—peripheral nervous system neoplasm	0.000115	0.000809	CcSEcCtD
Bosutinib—Anaphylactic shock—Cisplatin—peripheral nervous system neoplasm	0.000115	0.000809	CcSEcCtD
Bosutinib—Infection—Cisplatin—peripheral nervous system neoplasm	0.000114	0.000803	CcSEcCtD
Bosutinib—Vomiting—Topotecan—peripheral nervous system neoplasm	0.000114	0.000803	CcSEcCtD
Bosutinib—CHEK2—Vindesine—Vincristine—peripheral nervous system neoplasm	0.000113	0.0241	CbGdCrCtD
Bosutinib—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.000113	0.000796	CcSEcCtD
Bosutinib—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.000113	0.000796	CcSEcCtD
Bosutinib—Rash—Topotecan—peripheral nervous system neoplasm	0.000113	0.000796	CcSEcCtD
Bosutinib—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.000113	0.000795	CcSEcCtD
Bosutinib—Decreased appetite—Vincristine—peripheral nervous system neoplasm	0.000113	0.000795	CcSEcCtD
Bosutinib—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.000113	0.000793	CcSEcCtD
Bosutinib—Cough—Etoposide—peripheral nervous system neoplasm	0.000113	0.000792	CcSEcCtD
Bosutinib—Thrombocytopenia—Cisplatin—peripheral nervous system neoplasm	0.000113	0.000792	CcSEcCtD
Bosutinib—Blood creatinine increased—Epirubicin—peripheral nervous system neoplasm	0.000113	0.000792	CcSEcCtD
Bosutinib—Headache—Topotecan—peripheral nervous system neoplasm	0.000113	0.000791	CcSEcCtD
Bosutinib—Rash—Isotretinoin—peripheral nervous system neoplasm	0.000112	0.00079	CcSEcCtD
Bosutinib—Rash—Tretinoin—peripheral nervous system neoplasm	0.000112	0.00079	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.000112	0.00079	CcSEcCtD
Bosutinib—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000112	0.000789	CcSEcCtD
Bosutinib—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000112	0.000789	CcSEcCtD
Bosutinib—Fatigue—Vincristine—peripheral nervous system neoplasm	0.000112	0.000789	CcSEcCtD
Bosutinib—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000112	0.000786	CcSEcCtD
Bosutinib—Dehydration—Epirubicin—peripheral nervous system neoplasm	0.000112	0.000786	CcSEcCtD
Bosutinib—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.000112	0.000786	CcSEcCtD
Bosutinib—Headache—Tretinoin—peripheral nervous system neoplasm	0.000112	0.000785	CcSEcCtD
Bosutinib—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000112	0.000785	CcSEcCtD
Bosutinib—Feeling abnormal—Alitretinoin—peripheral nervous system neoplasm	0.000111	0.000782	CcSEcCtD
Bosutinib—Pain—Vincristine—peripheral nervous system neoplasm	0.000111	0.000782	CcSEcCtD
Bosutinib—Gastrointestinal haemorrhage—Doxorubicin—peripheral nervous system neoplasm	0.000111	0.000782	CcSEcCtD
Bosutinib—Rash—Melphalan—peripheral nervous system neoplasm	0.000111	0.000779	CcSEcCtD
Bosutinib—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000111	0.000779	CcSEcCtD
Bosutinib—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.00011	0.000776	CcSEcCtD
Bosutinib—Chest pain—Etoposide—peripheral nervous system neoplasm	0.00011	0.000773	CcSEcCtD
Bosutinib—Abdominal pain upper—Epirubicin—peripheral nervous system neoplasm	0.00011	0.000772	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.000109	0.000768	CcSEcCtD
Bosutinib—Discomfort—Etoposide—peripheral nervous system neoplasm	0.000109	0.000764	CcSEcCtD
Bosutinib—Aspartate aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000108	0.000761	CcSEcCtD
Bosutinib—Nasopharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000108	0.000756	CcSEcCtD
Bosutinib—Face oedema—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.000755	CcSEcCtD
Bosutinib—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.000107	0.000754	CcSEcCtD
Bosutinib—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.000107	0.00075	CcSEcCtD
Bosutinib—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000107	0.00075	CcSEcCtD
Bosutinib—Nausea—Topotecan—peripheral nervous system neoplasm	0.000107	0.00075	CcSEcCtD
Bosutinib—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000106	0.000748	CcSEcCtD
Bosutinib—Gastritis—Epirubicin—peripheral nervous system neoplasm	0.000106	0.000748	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000106	0.000745	CcSEcCtD
Bosutinib—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000106	0.000744	CcSEcCtD
Bosutinib—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000106	0.000744	CcSEcCtD
Bosutinib—ERBB3—Podofilox—Etoposide—peripheral nervous system neoplasm	0.000106	0.0225	CbGdCrCtD
Bosutinib—Anaphylactic shock—Etoposide—peripheral nervous system neoplasm	0.000105	0.000741	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000105	0.000737	CcSEcCtD
Bosutinib—Infection—Etoposide—peripheral nervous system neoplasm	0.000105	0.000736	CcSEcCtD
Bosutinib—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000104	0.000734	CcSEcCtD
Bosutinib—Nausea—Melphalan—peripheral nervous system neoplasm	0.000104	0.000734	CcSEcCtD
Bosutinib—Blood creatinine increased—Doxorubicin—peripheral nervous system neoplasm	0.000104	0.000732	CcSEcCtD
Bosutinib—Influenza—Epirubicin—peripheral nervous system neoplasm	0.000104	0.00073	CcSEcCtD
Bosutinib—ABL1—cerebellum—peripheral nervous system neoplasm	0.000104	0.0013	CbGeAlD
Bosutinib—Dehydration—Doxorubicin—peripheral nervous system neoplasm	0.000103	0.000727	CcSEcCtD
Bosutinib—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	0.000103	0.000725	CcSEcCtD
Bosutinib—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000103	0.000723	CcSEcCtD
Bosutinib—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000103	0.000723	CcSEcCtD
Bosutinib—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000103	0.000721	CcSEcCtD
Bosutinib—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000102	0.00072	CcSEcCtD
Bosutinib—Abdominal pain upper—Doxorubicin—peripheral nervous system neoplasm	0.000102	0.000714	CcSEcCtD
Bosutinib—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.000101	0.0446	CbGbCtD
Bosutinib—Aspartate aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.0001	0.000704	CcSEcCtD
Bosutinib—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.0001	0.000703	CcSEcCtD
Bosutinib—Bronchitis—Epirubicin—peripheral nervous system neoplasm	9.99e-05	0.000702	CcSEcCtD
Bosutinib—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	9.97e-05	0.0007	CcSEcCtD
Bosutinib—Nasopharyngitis—Doxorubicin—peripheral nervous system neoplasm	9.95e-05	0.000699	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	9.93e-05	0.000698	CcSEcCtD
Bosutinib—Pancytopenia—Epirubicin—peripheral nervous system neoplasm	9.87e-05	0.000694	CcSEcCtD
Bosutinib—Gastritis—Doxorubicin—peripheral nervous system neoplasm	9.84e-05	0.000692	CcSEcCtD
Bosutinib—Pain—Cisplatin—peripheral nervous system neoplasm	9.84e-05	0.000692	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	9.81e-05	0.00069	CcSEcCtD
Bosutinib—Neutropenia—Epirubicin—peripheral nervous system neoplasm	9.72e-05	0.000683	CcSEcCtD
Bosutinib—Asthenia—Alitretinoin—peripheral nervous system neoplasm	9.69e-05	0.000681	CcSEcCtD
Bosutinib—CYP3A4—Vincristine—peripheral nervous system neoplasm	9.66e-05	0.0427	CbGbCtD
Bosutinib—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	9.66e-05	0.000679	CcSEcCtD
Bosutinib—Influenza—Doxorubicin—peripheral nervous system neoplasm	9.61e-05	0.000676	CcSEcCtD
Bosutinib—Pruritus—Alitretinoin—peripheral nervous system neoplasm	9.55e-05	0.000672	CcSEcCtD
Bosutinib—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	9.48e-05	0.000666	CcSEcCtD
Bosutinib—Dyspnoea—Etoposide—peripheral nervous system neoplasm	9.4e-05	0.000661	CcSEcCtD
Bosutinib—Asthenia—Vincristine—peripheral nervous system neoplasm	9.34e-05	0.000656	CcSEcCtD
Bosutinib—Pneumonia—Epirubicin—peripheral nervous system neoplasm	9.32e-05	0.000655	CcSEcCtD
Bosutinib—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	9.26e-05	0.000651	CcSEcCtD
Bosutinib—Infestation—Epirubicin—peripheral nervous system neoplasm	9.26e-05	0.000651	CcSEcCtD
Bosutinib—Vomiting—Dactinomycin—peripheral nervous system neoplasm	9.26e-05	0.000651	CcSEcCtD
Bosutinib—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	9.25e-05	0.00065	CcSEcCtD
Bosutinib—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	9.24e-05	0.000649	CcSEcCtD
Bosutinib—Rash—Dactinomycin—peripheral nervous system neoplasm	9.18e-05	0.000645	CcSEcCtD
Bosutinib—Decreased appetite—Etoposide—peripheral nervous system neoplasm	9.16e-05	0.000644	CcSEcCtD
Bosutinib—Pancytopenia—Doxorubicin—peripheral nervous system neoplasm	9.13e-05	0.000642	CcSEcCtD
Bosutinib—Renal failure—Epirubicin—peripheral nervous system neoplasm	9.11e-05	0.00064	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	9.1e-05	0.00064	CcSEcCtD
Bosutinib—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	9.1e-05	0.000639	CcSEcCtD
Bosutinib—Fatigue—Etoposide—peripheral nervous system neoplasm	9.09e-05	0.000639	CcSEcCtD
Bosutinib—Pain—Etoposide—peripheral nervous system neoplasm	9.01e-05	0.000634	CcSEcCtD
Bosutinib—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	8.99e-05	0.000632	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	8.94e-05	0.000628	CcSEcCtD
Bosutinib—Dizziness—Alitretinoin—peripheral nervous system neoplasm	8.93e-05	0.000628	CcSEcCtD
Bosutinib—Diarrhoea—Vincristine—peripheral nervous system neoplasm	8.9e-05	0.000626	CcSEcCtD
Bosutinib—CYP3A4—Etoposide—peripheral nervous system neoplasm	8.85e-05	0.0392	CbGbCtD
Bosutinib—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	8.76e-05	0.000616	CcSEcCtD
Bosutinib—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	8.69e-05	0.000611	CcSEcCtD
Bosutinib—Nausea—Dactinomycin—peripheral nervous system neoplasm	8.65e-05	0.000608	CcSEcCtD
Bosutinib—Agranulocytosis—Epirubicin—peripheral nervous system neoplasm	8.65e-05	0.000608	CcSEcCtD
Bosutinib—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	8.62e-05	0.000606	CcSEcCtD
Bosutinib—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	8.62e-05	0.000606	CcSEcCtD
Bosutinib—Dizziness—Vincristine—peripheral nervous system neoplasm	8.61e-05	0.000605	CcSEcCtD
Bosutinib—Vomiting—Alitretinoin—peripheral nervous system neoplasm	8.59e-05	0.000604	CcSEcCtD
Bosutinib—Infestation—Doxorubicin—peripheral nervous system neoplasm	8.57e-05	0.000603	CcSEcCtD
Bosutinib—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	8.57e-05	0.000603	CcSEcCtD
Bosutinib—Rash—Alitretinoin—peripheral nervous system neoplasm	8.51e-05	0.000598	CcSEcCtD
Bosutinib—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	8.51e-05	0.000598	CcSEcCtD
Bosutinib—Headache—Alitretinoin—peripheral nervous system neoplasm	8.46e-05	0.000595	CcSEcCtD
Bosutinib—Renal failure—Doxorubicin—peripheral nervous system neoplasm	8.43e-05	0.000592	CcSEcCtD
Bosutinib—Urticaria—Etoposide—peripheral nervous system neoplasm	8.37e-05	0.000589	CcSEcCtD
Bosutinib—Body temperature increased—Etoposide—peripheral nervous system neoplasm	8.33e-05	0.000586	CcSEcCtD
Bosutinib—Abdominal pain—Etoposide—peripheral nervous system neoplasm	8.33e-05	0.000586	CcSEcCtD
Bosutinib—Hepatitis—Epirubicin—peripheral nervous system neoplasm	8.32e-05	0.000585	CcSEcCtD
Bosutinib—Vomiting—Vincristine—peripheral nervous system neoplasm	8.27e-05	0.000582	CcSEcCtD
Bosutinib—Asthenia—Cisplatin—peripheral nervous system neoplasm	8.26e-05	0.00058	CcSEcCtD
Bosutinib—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	8.21e-05	0.000577	CcSEcCtD
Bosutinib—Rash—Vincristine—peripheral nervous system neoplasm	8.2e-05	0.000577	CcSEcCtD
Bosutinib—Dermatitis—Vincristine—peripheral nervous system neoplasm	8.2e-05	0.000576	CcSEcCtD
Bosutinib—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	8.19e-05	0.000576	CcSEcCtD
Bosutinib—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	8.17e-05	0.000574	CcSEcCtD
Bosutinib—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	8.15e-05	0.000573	CcSEcCtD
Bosutinib—Headache—Vincristine—peripheral nervous system neoplasm	8.15e-05	0.000573	CcSEcCtD
Bosutinib—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	8.11e-05	0.00057	CcSEcCtD
Bosutinib—Nausea—Alitretinoin—peripheral nervous system neoplasm	8.02e-05	0.000564	CcSEcCtD
Bosutinib—Agranulocytosis—Doxorubicin—peripheral nervous system neoplasm	8e-05	0.000562	CcSEcCtD
Bosutinib—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	7.87e-05	0.000553	CcSEcCtD
Bosutinib—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	7.86e-05	0.000553	CcSEcCtD
Bosutinib—Tinnitus—Epirubicin—peripheral nervous system neoplasm	7.75e-05	0.000545	CcSEcCtD
Bosutinib—Nausea—Vincristine—peripheral nervous system neoplasm	7.73e-05	0.000543	CcSEcCtD
Bosutinib—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	7.72e-05	0.000543	CcSEcCtD
Bosutinib—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	7.7e-05	0.000541	CcSEcCtD
Bosutinib—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	7.6e-05	0.000534	CcSEcCtD
Bosutinib—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	7.58e-05	0.000533	CcSEcCtD
Bosutinib—Asthenia—Etoposide—peripheral nervous system neoplasm	7.56e-05	0.000532	CcSEcCtD
Bosutinib—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	7.56e-05	0.000532	CcSEcCtD
Bosutinib—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	7.54e-05	0.00053	CcSEcCtD
Bosutinib—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	7.51e-05	0.000528	CcSEcCtD
Bosutinib—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	7.5e-05	0.000527	CcSEcCtD
Bosutinib—Pruritus—Etoposide—peripheral nervous system neoplasm	7.46e-05	0.000524	CcSEcCtD
Bosutinib—ABCB1—trigeminal ganglion—peripheral nervous system neoplasm	7.4e-05	0.000929	CbGeAlD
Bosutinib—Vomiting—Cisplatin—peripheral nervous system neoplasm	7.32e-05	0.000514	CcSEcCtD
Bosutinib—ERBB3—Vinblastine—Vincristine—peripheral nervous system neoplasm	7.28e-05	0.0155	CbGdCrCtD
Bosutinib—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	7.28e-05	0.000511	CcSEcCtD
Bosutinib—Rash—Cisplatin—peripheral nervous system neoplasm	7.26e-05	0.00051	CcSEcCtD
Bosutinib—Dermatitis—Cisplatin—peripheral nervous system neoplasm	7.25e-05	0.000509	CcSEcCtD
Bosutinib—Malnutrition—Epirubicin—peripheral nervous system neoplasm	7.24e-05	0.000509	CcSEcCtD
Bosutinib—Diarrhoea—Etoposide—peripheral nervous system neoplasm	7.21e-05	0.000507	CcSEcCtD
Bosutinib—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	7.18e-05	0.000504	CcSEcCtD
Bosutinib—CHEK2—Vinorelbine—Vincristine—peripheral nervous system neoplasm	7.15e-05	0.0152	CbGdCrCtD
Bosutinib—CHEK2—Teniposide—Etoposide—peripheral nervous system neoplasm	7.15e-05	0.0152	CbGdCrCtD
Bosutinib—CHEK2—Podofilox—Etoposide—peripheral nervous system neoplasm	7.15e-05	0.0152	CbGdCrCtD
Bosutinib—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	7.14e-05	0.000502	CcSEcCtD
Bosutinib—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	7.09e-05	0.000498	CcSEcCtD
Bosutinib—Back pain—Epirubicin—peripheral nervous system neoplasm	7e-05	0.000492	CcSEcCtD
Bosutinib—Dizziness—Etoposide—peripheral nervous system neoplasm	6.97e-05	0.00049	CcSEcCtD
Bosutinib—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	6.95e-05	0.000489	CcSEcCtD
Bosutinib—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	6.94e-05	0.000487	CcSEcCtD
Bosutinib—Nausea—Cisplatin—peripheral nervous system neoplasm	6.83e-05	0.00048	CcSEcCtD
Bosutinib—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	6.72e-05	0.000472	CcSEcCtD
Bosutinib—Vomiting—Etoposide—peripheral nervous system neoplasm	6.7e-05	0.000471	CcSEcCtD
Bosutinib—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	6.7e-05	0.000471	CcSEcCtD
Bosutinib—Anaemia—Epirubicin—peripheral nervous system neoplasm	6.69e-05	0.00047	CcSEcCtD
Bosutinib—Rash—Etoposide—peripheral nervous system neoplasm	6.65e-05	0.000467	CcSEcCtD
Bosutinib—Dermatitis—Etoposide—peripheral nervous system neoplasm	6.64e-05	0.000467	CcSEcCtD
Bosutinib—Headache—Etoposide—peripheral nervous system neoplasm	6.6e-05	0.000464	CcSEcCtD
Bosutinib—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	6.56e-05	0.000461	CcSEcCtD
Bosutinib—Malaise—Epirubicin—peripheral nervous system neoplasm	6.53e-05	0.000459	CcSEcCtD
Bosutinib—Leukopenia—Epirubicin—peripheral nervous system neoplasm	6.48e-05	0.000456	CcSEcCtD
Bosutinib—Back pain—Doxorubicin—peripheral nervous system neoplasm	6.48e-05	0.000455	CcSEcCtD
Bosutinib—Cough—Epirubicin—peripheral nervous system neoplasm	6.32e-05	0.000444	CcSEcCtD
Bosutinib—Nausea—Etoposide—peripheral nervous system neoplasm	6.26e-05	0.00044	CcSEcCtD
Bosutinib—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	6.22e-05	0.000437	CcSEcCtD
Bosutinib—Anaemia—Doxorubicin—peripheral nervous system neoplasm	6.19e-05	0.000435	CcSEcCtD
Bosutinib—Arthralgia—Epirubicin—peripheral nervous system neoplasm	6.16e-05	0.000433	CcSEcCtD
Bosutinib—Myalgia—Epirubicin—peripheral nervous system neoplasm	6.16e-05	0.000433	CcSEcCtD
Bosutinib—Chest pain—Epirubicin—peripheral nervous system neoplasm	6.16e-05	0.000433	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	6.12e-05	0.00043	CcSEcCtD
Bosutinib—Discomfort—Epirubicin—peripheral nervous system neoplasm	6.09e-05	0.000428	CcSEcCtD
Bosutinib—Malaise—Doxorubicin—peripheral nervous system neoplasm	6.04e-05	0.000425	CcSEcCtD
Bosutinib—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	6.04e-05	0.0267	CbGbCtD
Bosutinib—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	6e-05	0.000421	CcSEcCtD
Bosutinib—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	5.91e-05	0.000415	CcSEcCtD
Bosutinib—Oedema—Epirubicin—peripheral nervous system neoplasm	5.91e-05	0.000415	CcSEcCtD
Bosutinib—Infection—Epirubicin—peripheral nervous system neoplasm	5.87e-05	0.000413	CcSEcCtD
Bosutinib—Cough—Doxorubicin—peripheral nervous system neoplasm	5.85e-05	0.000411	CcSEcCtD
Bosutinib—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	5.79e-05	0.000407	CcSEcCtD
Bosutinib—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	5.79e-05	0.000407	CcSEcCtD
Bosutinib—Skin disorder—Epirubicin—peripheral nervous system neoplasm	5.74e-05	0.000403	CcSEcCtD
Bosutinib—Chest pain—Doxorubicin—peripheral nervous system neoplasm	5.7e-05	0.000401	CcSEcCtD
Bosutinib—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	5.7e-05	0.000401	CcSEcCtD
Bosutinib—Myalgia—Doxorubicin—peripheral nervous system neoplasm	5.7e-05	0.000401	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	5.66e-05	0.000398	CcSEcCtD
Bosutinib—Discomfort—Doxorubicin—peripheral nervous system neoplasm	5.64e-05	0.000396	CcSEcCtD
Bosutinib—Oedema—Doxorubicin—peripheral nervous system neoplasm	5.47e-05	0.000384	CcSEcCtD
Bosutinib—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	5.47e-05	0.000384	CcSEcCtD
Bosutinib—Infection—Doxorubicin—peripheral nervous system neoplasm	5.43e-05	0.000382	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	5.38e-05	0.000378	CcSEcCtD
Bosutinib—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	5.36e-05	0.000377	CcSEcCtD
Bosutinib—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	5.35e-05	0.000376	CcSEcCtD
Bosutinib—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	5.31e-05	0.000373	CcSEcCtD
Bosutinib—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	5.27e-05	0.00037	CcSEcCtD
Bosutinib—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	5.14e-05	0.000361	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	5.1e-05	0.000359	CcSEcCtD
Bosutinib—Fatigue—Epirubicin—peripheral nervous system neoplasm	5.09e-05	0.000358	CcSEcCtD
Bosutinib—CSK—Daunorubicin—Epirubicin—peripheral nervous system neoplasm	5.09e-05	0.0108	CbGdCrCtD
Bosutinib—CSK—Doxorubicin—Epirubicin—peripheral nervous system neoplasm	5.09e-05	0.0108	CbGdCrCtD
Bosutinib—Pain—Epirubicin—peripheral nervous system neoplasm	5.05e-05	0.000355	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	4.98e-05	0.00035	CcSEcCtD
Bosutinib—CHEK2—Vinblastine—Vincristine—peripheral nervous system neoplasm	4.92e-05	0.0105	CbGdCrCtD
Bosutinib—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	4.87e-05	0.000343	CcSEcCtD
Bosutinib—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	4.87e-05	0.000342	CcSEcCtD
Bosutinib—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	4.83e-05	0.00034	CcSEcCtD
Bosutinib—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	4.75e-05	0.000334	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	4.72e-05	0.000332	CcSEcCtD
Bosutinib—Fatigue—Doxorubicin—peripheral nervous system neoplasm	4.71e-05	0.000331	CcSEcCtD
Bosutinib—CSK—Epirubicin—Doxorubicin—peripheral nervous system neoplasm	4.71e-05	0.01	CbGdCrCtD
Bosutinib—CSK—Daunorubicin—Doxorubicin—peripheral nervous system neoplasm	4.71e-05	0.01	CbGdCrCtD
Bosutinib—Urticaria—Epirubicin—peripheral nervous system neoplasm	4.69e-05	0.00033	CcSEcCtD
Bosutinib—Pain—Doxorubicin—peripheral nervous system neoplasm	4.68e-05	0.000329	CcSEcCtD
Bosutinib—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	4.67e-05	0.000328	CcSEcCtD
Bosutinib—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	4.67e-05	0.000328	CcSEcCtD
Bosutinib—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	4.51e-05	0.000317	CcSEcCtD
Bosutinib—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	4.47e-05	0.000314	CcSEcCtD
Bosutinib—Urticaria—Doxorubicin—peripheral nervous system neoplasm	4.34e-05	0.000305	CcSEcCtD
Bosutinib—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	4.32e-05	0.000304	CcSEcCtD
Bosutinib—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	4.32e-05	0.000304	CcSEcCtD
Bosutinib—Asthenia—Epirubicin—peripheral nervous system neoplasm	4.24e-05	0.000298	CcSEcCtD
Bosutinib—Pruritus—Epirubicin—peripheral nervous system neoplasm	4.18e-05	0.000294	CcSEcCtD
Bosutinib—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	4.04e-05	0.000284	CcSEcCtD
Bosutinib—Asthenia—Doxorubicin—peripheral nervous system neoplasm	3.92e-05	0.000276	CcSEcCtD
Bosutinib—Dizziness—Epirubicin—peripheral nervous system neoplasm	3.91e-05	0.000275	CcSEcCtD
Bosutinib—Pruritus—Doxorubicin—peripheral nervous system neoplasm	3.87e-05	0.000272	CcSEcCtD
Bosutinib—Vomiting—Epirubicin—peripheral nervous system neoplasm	3.76e-05	0.000264	CcSEcCtD
Bosutinib—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	3.74e-05	0.000263	CcSEcCtD
Bosutinib—CHEK2—Doxorubicin—Epirubicin—peripheral nervous system neoplasm	3.73e-05	0.00792	CbGdCrCtD
Bosutinib—Rash—Epirubicin—peripheral nervous system neoplasm	3.73e-05	0.000262	CcSEcCtD
Bosutinib—Dermatitis—Epirubicin—peripheral nervous system neoplasm	3.72e-05	0.000262	CcSEcCtD
Bosutinib—Headache—Epirubicin—peripheral nervous system neoplasm	3.7e-05	0.00026	CcSEcCtD
Bosutinib—Dizziness—Doxorubicin—peripheral nervous system neoplasm	3.62e-05	0.000254	CcSEcCtD
Bosutinib—ABL1—Daunorubicin—Epirubicin—peripheral nervous system neoplasm	3.56e-05	0.00756	CbGdCrCtD
Bosutinib—ABL1—Idarubicin—Epirubicin—peripheral nervous system neoplasm	3.56e-05	0.00756	CbGdCrCtD
Bosutinib—ABL1—Doxorubicin—Epirubicin—peripheral nervous system neoplasm	3.56e-05	0.00756	CbGdCrCtD
Bosutinib—Nausea—Epirubicin—peripheral nervous system neoplasm	3.51e-05	0.000247	CcSEcCtD
Bosutinib—Vomiting—Doxorubicin—peripheral nervous system neoplasm	3.48e-05	0.000244	CcSEcCtD
Bosutinib—CHEK2—Epirubicin—Doxorubicin—peripheral nervous system neoplasm	3.45e-05	0.00733	CbGdCrCtD
Bosutinib—Rash—Doxorubicin—peripheral nervous system neoplasm	3.45e-05	0.000242	CcSEcCtD
Bosutinib—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	3.44e-05	0.000242	CcSEcCtD
Bosutinib—Headache—Doxorubicin—peripheral nervous system neoplasm	3.43e-05	0.000241	CcSEcCtD
Bosutinib—ABL1—Idarubicin—Doxorubicin—peripheral nervous system neoplasm	3.29e-05	0.00699	CbGdCrCtD
Bosutinib—ABL1—Epirubicin—Doxorubicin—peripheral nervous system neoplasm	3.29e-05	0.00699	CbGdCrCtD
Bosutinib—ABL1—Daunorubicin—Doxorubicin—peripheral nervous system neoplasm	3.29e-05	0.00699	CbGdCrCtD
Bosutinib—Nausea—Doxorubicin—peripheral nervous system neoplasm	3.25e-05	0.000228	CcSEcCtD
Bosutinib—ABCB1—cerebellum—peripheral nervous system neoplasm	3.23e-05	0.000405	CbGeAlD
Bosutinib—EGFR—Immune System—ERBB2—peripheral nervous system neoplasm	2.06e-06	1.16e-05	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—HRAS—peripheral nervous system neoplasm	2.06e-06	1.16e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—PTPN11—peripheral nervous system neoplasm	2.05e-06	1.16e-05	CbGpPWpGaD
Bosutinib—LYN—Innate Immune System—AKT1—peripheral nervous system neoplasm	2.04e-06	1.15e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.03e-06	1.15e-05	CbGpPWpGaD
Bosutinib—ABL1—Innate Immune System—AKT1—peripheral nervous system neoplasm	2.03e-06	1.14e-05	CbGpPWpGaD
Bosutinib—PTK2B—Immune System—AKT1—peripheral nervous system neoplasm	2.03e-06	1.14e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.02e-06	1.14e-05	CbGpPWpGaD
Bosutinib—HCK—Disease—AKT1—peripheral nervous system neoplasm	2.02e-06	1.14e-05	CbGpPWpGaD
Bosutinib—FYN—Innate Immune System—AKT1—peripheral nervous system neoplasm	2.01e-06	1.13e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	2e-06	1.13e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Innate Immune System—AKT1—peripheral nervous system neoplasm	2e-06	1.13e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.99e-06	1.12e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—ERBB2—peripheral nervous system neoplasm	1.98e-06	1.12e-05	CbGpPWpGaD
Bosutinib—BLK—Immune System—AKT1—peripheral nervous system neoplasm	1.98e-06	1.12e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.98e-06	1.12e-05	CbGpPWpGaD
Bosutinib—FGR—Immune System—AKT1—peripheral nervous system neoplasm	1.98e-06	1.11e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.97e-06	1.11e-05	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—HRAS—peripheral nervous system neoplasm	1.97e-06	1.11e-05	CbGpPWpGaD
Bosutinib—EGFR—Developmental Biology—AKT1—peripheral nervous system neoplasm	1.97e-06	1.11e-05	CbGpPWpGaD
Bosutinib—LYN—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	1.96e-06	1.1e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.96e-06	1.1e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.95e-06	1.1e-05	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—TP53—peripheral nervous system neoplasm	1.95e-06	1.1e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.95e-06	1.1e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.94e-06	1.09e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.93e-06	1.09e-05	CbGpPWpGaD
Bosutinib—FYN—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	1.93e-06	1.09e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—NRAS—peripheral nervous system neoplasm	1.93e-06	1.09e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.92e-06	1.08e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.91e-06	1.08e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.91e-06	1.08e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—BCHE—peripheral nervous system neoplasm	1.91e-06	1.07e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.91e-06	1.07e-05	CbGpPWpGaD
Bosutinib—ERBB4—Disease—AKT1—peripheral nervous system neoplasm	1.9e-06	1.07e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—ERBB2—peripheral nervous system neoplasm	1.9e-06	1.07e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—HRAS—peripheral nervous system neoplasm	1.9e-06	1.07e-05	CbGpPWpGaD
Bosutinib—ERBB3—Disease—HRAS—peripheral nervous system neoplasm	1.9e-06	1.07e-05	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—HRAS—peripheral nervous system neoplasm	1.9e-06	1.07e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.89e-06	1.07e-05	CbGpPWpGaD
Bosutinib—EGFR—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	1.89e-06	1.06e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.89e-06	1.06e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.89e-06	1.06e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—NRAS—peripheral nervous system neoplasm	1.88e-06	1.06e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.88e-06	1.06e-05	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—HRAS—peripheral nervous system neoplasm	1.87e-06	1.05e-05	CbGpPWpGaD
Bosutinib—LCK—Hemostasis—AKT1—peripheral nervous system neoplasm	1.86e-06	1.05e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.84e-06	1.04e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—NRAS—peripheral nervous system neoplasm	1.84e-06	1.04e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—NRAS—peripheral nervous system neoplasm	1.83e-06	1.03e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—HRAS—peripheral nervous system neoplasm	1.83e-06	1.03e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—ERBB2—peripheral nervous system neoplasm	1.83e-06	1.03e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.83e-06	1.03e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.83e-06	1.03e-05	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	1.82e-06	1.03e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.82e-06	1.02e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.82e-06	1.02e-05	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—AKT1—peripheral nervous system neoplasm	1.82e-06	1.02e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—NRAS—peripheral nervous system neoplasm	1.81e-06	1.02e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.81e-06	1.02e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—HRAS—peripheral nervous system neoplasm	1.81e-06	1.02e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—NRAS—peripheral nervous system neoplasm	1.8e-06	1.02e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—TH—peripheral nervous system neoplasm	1.79e-06	1.01e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—NRAS—peripheral nervous system neoplasm	1.78e-06	1e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.76e-06	9.9e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.76e-06	9.9e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—ERBB2—peripheral nervous system neoplasm	1.76e-06	9.89e-06	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.75e-06	9.84e-06	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—AKT1—peripheral nervous system neoplasm	1.74e-06	9.78e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—NRAS—peripheral nervous system neoplasm	1.74e-06	9.78e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.71e-06	9.65e-06	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—HRAS—peripheral nervous system neoplasm	1.71e-06	9.65e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.7e-06	9.58e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.69e-06	9.54e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.68e-06	9.49e-06	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—HRAS—peripheral nervous system neoplasm	1.68e-06	9.45e-06	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—AKT1—peripheral nervous system neoplasm	1.68e-06	9.45e-06	CbGpPWpGaD
Bosutinib—ERBB3—Disease—AKT1—peripheral nervous system neoplasm	1.68e-06	9.45e-06	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—AKT1—peripheral nervous system neoplasm	1.67e-06	9.43e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—NRAS—peripheral nervous system neoplasm	1.67e-06	9.43e-06	CbGpPWpGaD
Bosutinib—EGFR—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	1.67e-06	9.39e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—NRAS—peripheral nervous system neoplasm	1.67e-06	9.38e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—MYC—peripheral nervous system neoplasm	1.66e-06	9.34e-06	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—AKT1—peripheral nervous system neoplasm	1.65e-06	9.27e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.64e-06	9.22e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.62e-06	9.14e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—ERBB2—peripheral nervous system neoplasm	1.62e-06	9.13e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.62e-06	9.12e-06	CbGpPWpGaD
Bosutinib—PTK2—Immune System—AKT1—peripheral nervous system neoplasm	1.62e-06	9.11e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—MYC—peripheral nervous system neoplasm	1.62e-06	9.11e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—HRAS—peripheral nervous system neoplasm	1.61e-06	9.09e-06	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—HRAS—peripheral nervous system neoplasm	1.61e-06	9.08e-06	CbGpPWpGaD
Bosutinib—LCK—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	1.61e-06	9.05e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.6e-06	9e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.6e-06	8.99e-06	CbGpPWpGaD
Bosutinib—YES1—Immune System—AKT1—peripheral nervous system neoplasm	1.6e-06	8.98e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.58e-06	8.89e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—NRAS—peripheral nervous system neoplasm	1.57e-06	8.82e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.57e-06	8.81e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—MYC—peripheral nervous system neoplasm	1.56e-06	8.78e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.56e-06	8.76e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—MYC—peripheral nervous system neoplasm	1.55e-06	8.73e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.54e-06	8.69e-06	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.54e-06	8.69e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.54e-06	8.68e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.53e-06	8.63e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.51e-06	8.53e-06	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—AKT1—peripheral nervous system neoplasm	1.51e-06	8.52e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.51e-06	8.5e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—NRAS—peripheral nervous system neoplasm	1.51e-06	8.5e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.51e-06	8.49e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.5e-06	8.44e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.49e-06	8.38e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.49e-06	8.38e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.49e-06	8.37e-06	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—AKT1—peripheral nervous system neoplasm	1.48e-06	8.35e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—GNAS—peripheral nervous system neoplasm	1.46e-06	8.24e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.45e-06	8.17e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—NRAS—peripheral nervous system neoplasm	1.45e-06	8.14e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.44e-06	8.13e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.44e-06	8.13e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.44e-06	8.13e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.44e-06	8.09e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.43e-06	8.07e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.43e-06	8.03e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—AKT1—peripheral nervous system neoplasm	1.43e-06	8.02e-06	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—AKT1—peripheral nervous system neoplasm	1.42e-06	8.01e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.42e-06	8e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.41e-06	7.94e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—HRAS—peripheral nervous system neoplasm	1.41e-06	7.94e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.4e-06	7.88e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—NRAS—peripheral nervous system neoplasm	1.39e-06	7.85e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.39e-06	7.84e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.39e-06	7.83e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	1.39e-06	7.83e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.38e-06	7.78e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.38e-06	7.78e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—HRAS—peripheral nervous system neoplasm	1.38e-06	7.75e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.36e-06	7.67e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—HRAS—peripheral nervous system neoplasm	1.35e-06	7.59e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—MYC—peripheral nervous system neoplasm	1.35e-06	7.59e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—HRAS—peripheral nervous system neoplasm	1.34e-06	7.55e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—NRAS—peripheral nervous system neoplasm	1.34e-06	7.53e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.33e-06	7.51e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.33e-06	7.5e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.33e-06	7.49e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.33e-06	7.48e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—HRAS—peripheral nervous system neoplasm	1.33e-06	7.47e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—HRAS—peripheral nervous system neoplasm	1.32e-06	7.43e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.31e-06	7.4e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—HRAS—peripheral nervous system neoplasm	1.3e-06	7.33e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—MYC—peripheral nervous system neoplasm	1.3e-06	7.31e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.28e-06	7.22e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.28e-06	7.18e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—HRAS—peripheral nervous system neoplasm	1.27e-06	7.16e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.27e-06	7.13e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.25e-06	7.06e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.25e-06	7.02e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—AKT1—peripheral nervous system neoplasm	1.25e-06	7.01e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.24e-06	6.98e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—NRAS—peripheral nervous system neoplasm	1.23e-06	6.95e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—HRAS—peripheral nervous system neoplasm	1.23e-06	6.9e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.22e-06	6.88e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.22e-06	6.87e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.22e-06	6.87e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—HRAS—peripheral nervous system neoplasm	1.22e-06	6.86e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.22e-06	6.85e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—AKT1—peripheral nervous system neoplasm	1.22e-06	6.84e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.21e-06	6.8e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.19e-06	6.71e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—AKT1—peripheral nervous system neoplasm	1.19e-06	6.7e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.18e-06	6.67e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—AKT1—peripheral nervous system neoplasm	1.18e-06	6.67e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.18e-06	6.62e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	1.17e-06	6.61e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.17e-06	6.6e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—AKT1—peripheral nervous system neoplasm	1.17e-06	6.6e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.17e-06	6.58e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.17e-06	6.57e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—AKT1—peripheral nervous system neoplasm	1.17e-06	6.56e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.16e-06	6.56e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.16e-06	6.54e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.16e-06	6.52e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—AKT1—peripheral nervous system neoplasm	1.15e-06	6.47e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—MYC—peripheral nervous system neoplasm	1.15e-06	6.47e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—HRAS—peripheral nervous system neoplasm	1.15e-06	6.45e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.14e-06	6.4e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.13e-06	6.38e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—AKT1—peripheral nervous system neoplasm	1.12e-06	6.32e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.12e-06	6.31e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.11e-06	6.25e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.11e-06	6.24e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.11e-06	6.24e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—HRAS—peripheral nervous system neoplasm	1.1e-06	6.22e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	1.1e-06	6.22e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.09e-06	6.15e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.09e-06	6.14e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.09e-06	6.12e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—AKT1—peripheral nervous system neoplasm	1.08e-06	6.09e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—AKT1—peripheral nervous system neoplasm	1.08e-06	6.06e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—HRAS—peripheral nervous system neoplasm	1.06e-06	5.96e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.05e-06	5.89e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.04e-06	5.88e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.03e-06	5.81e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.03e-06	5.8e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—HRAS—peripheral nervous system neoplasm	1.02e-06	5.74e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.01e-06	5.7e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—AKT1—peripheral nervous system neoplasm	1.01e-06	5.7e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	9.79e-07	5.51e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—HRAS—peripheral nervous system neoplasm	9.78e-07	5.51e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NRAS—peripheral nervous system neoplasm	9.76e-07	5.5e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—AKT1—peripheral nervous system neoplasm	9.75e-07	5.49e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TP53—peripheral nervous system neoplasm	9.54e-07	5.37e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MYC—peripheral nervous system neoplasm	9.44e-07	5.31e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—AKT1—peripheral nervous system neoplasm	9.34e-07	5.26e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TP53—peripheral nervous system neoplasm	9.31e-07	5.24e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—AKT1—peripheral nervous system neoplasm	9.21e-07	5.19e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	9.12e-07	5.13e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TP53—peripheral nervous system neoplasm	9.11e-07	5.13e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MYC—peripheral nervous system neoplasm	9.09e-07	5.12e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—HRAS—peripheral nervous system neoplasm	9.03e-07	5.08e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	9.02e-07	5.08e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—AKT1—peripheral nervous system neoplasm	9.01e-07	5.07e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TP53—peripheral nervous system neoplasm	8.97e-07	5.05e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TP53—peripheral nervous system neoplasm	8.92e-07	5.02e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—HRAS—peripheral nervous system neoplasm	8.9e-07	5.01e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	8.85e-07	4.98e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—HRAS—peripheral nervous system neoplasm	8.71e-07	4.91e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NRAS—peripheral nervous system neoplasm	8.64e-07	4.87e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—AKT1—peripheral nervous system neoplasm	8.63e-07	4.86e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—HRAS—peripheral nervous system neoplasm	8.58e-07	4.83e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	8.53e-07	4.8e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	8.05e-07	4.53e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MYC—peripheral nervous system neoplasm	8.05e-07	4.53e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—AKT1—peripheral nervous system neoplasm	7.97e-07	4.49e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—AKT1—peripheral nervous system neoplasm	7.86e-07	4.42e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TP53—peripheral nervous system neoplasm	7.75e-07	4.36e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—AKT1—peripheral nervous system neoplasm	7.69e-07	4.33e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—AKT1—peripheral nervous system neoplasm	7.57e-07	4.26e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	7.53e-07	4.24e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TP53—peripheral nervous system neoplasm	7.47e-07	4.2e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—HRAS—peripheral nervous system neoplasm	7.41e-07	4.17e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—HRAS—peripheral nervous system neoplasm	7.14e-07	4.02e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TP53—peripheral nervous system neoplasm	6.61e-07	3.72e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—AKT1—peripheral nervous system neoplasm	6.54e-07	3.68e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—HRAS—peripheral nervous system neoplasm	6.32e-07	3.56e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—AKT1—peripheral nervous system neoplasm	6.31e-07	3.55e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—AKT1—peripheral nervous system neoplasm	5.58e-07	3.14e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	3.95e-07	2.22e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	2.43e-07	1.37e-06	CbGpPWpGaD
